AQST - Aquestive Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Warren,
United States
Type: Equity
AQST price evolution
AQST
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $89.87 | $95.2 | $23.87 | |
| Short term investments | ||||
| Net receivables | $9.68 | $6 | $8.32 | $8.47 |
| Inventory | $7.02 | $6.97 | $7.73 | $6.77 |
| Total current assets | $96.57 | $104.01 | $113.38 | $40.97 |
| Long term investments | ||||
| Property, plant & equipment | $9.16 | $9.36 | $9.49 | $9.74 |
| Goodwill & intangible assets | $1.24 | $1.28 | ||
| Total noncurrent assets | $13.59 | $16.14 | $16.45 | |
| Total investments | ||||
| Total assets | $109.96 | $117.61 | $129.52 | $57.42 |
| Current liabilities | ||||
| Accounts payable | $7.57 | $5.7 | $10.52 | $8.93 |
| Deferred revenue | $22.8 | $33.51 | $33.9 | |
| Short long term debt | $1.48 | $1.35 | $1.33 | |
| Total current liabilities | $15.15 | $13.89 | $18.06 | $18.31 |
| Long term debt | $31.25 | $115.41 | $113.79 | $111.24 |
| Total noncurrent liabilities | $139.19 | $147.77 | $145.6 | |
| Total debt | $116.88 | $115.14 | $112.57 | |
| Total liabilities | $155.38 | $153.08 | $165.82 | $163.91 |
| Shareholders' equity | ||||
| Retained earnings | -$346.16 | -$334.65 | -$331.9 | -$319.08 |
| Other shareholder equity | ||||
| Total shareholder equity | -$35.48 | -$36.3 | -$106.49 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $23.87 | $27.27 | $28.02 | $31.81 |
| Short term investments | ||||
| Net receivables | $8.47 | $4.7 | $12.12 | $6.96 |
| Inventory | $6.77 | $5.78 | $4.04 | $2.46 |
| Total current assets | $40.97 | $39.89 | $47.26 | $44.63 |
| Long term investments | ||||
| Property, plant & equipment | $9.74 | $7.9 | $7.78 | $10.32 |
| Goodwill & intangible assets | $1.28 | $1.44 | $0.05 | $0.1 |
| Total noncurrent assets | $16.45 | $17.18 | $14.73 | $18.26 |
| Total investments | ||||
| Total assets | $57.42 | $55.67 | $61.99 | $62.88 |
| Current liabilities | ||||
| Accounts payable | $8.93 | $9.95 | $8.31 | $7.09 |
| Deferred revenue | $33.9 | $32.93 | $7.89 | $4.33 |
| Short long term debt | $1.33 | $20.1 | $4.15 | $4.75 |
| Total current liabilities | $18.31 | $39.68 | $21.96 | $21.1 |
| Long term debt | $111.24 | $33.45 | $112.56 | $84.7 |
| Total noncurrent liabilities | $145.6 | $136.1 | $122.16 | $90.28 |
| Total debt | $112.57 | $122.75 | $116.7 | $89.45 |
| Total liabilities | $163.91 | $174.23 | $144.13 | $111.38 |
| Shareholders' equity | ||||
| Retained earnings | -$319.08 | -$311.21 | -$256.8 | -$186.26 |
| Other shareholder equity | ||||
| Total shareholder equity | -$106.49 | -$118.55 | -$82.13 | -$48.5 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12.05 | $13.21 | ||
| Cost of revenue | $4.39 | $4.68 | ||
| Gross Profit | $7.66 | $8.53 | ||
| Operating activities | ||||
| Research & development | $5.93 | $2.89 | ||
| Selling, general & administrative | $10.69 | $9.55 | ||
| Total operating expenses | $16.62 | $12.44 | ||
| Operating income | -$8.96 | -$3.91 | ||
| Income from continuing operations | ||||
| EBIT | -$8.63 | -$4.78 | ||
| Income tax expense | $0.1 | |||
| Interest expense | $4.2 | $3.23 | ||
| Net income | ||||
| Net income | -$12.83 | -$8.11 | ||
| Income (for common shares) | -$12.83 | -$8.11 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $50.58 | $47.68 | $50.83 | $45.85 |
| Cost of revenue | $20.83 | $19.39 | $14.99 | $12.96 |
| Gross Profit | $29.75 | $28.29 | $35.84 | $32.88 |
| Operating activities | ||||
| Research & development | $13.1 | $17.48 | $17.05 | $19.89 |
| Selling, general & administrative | $31.75 | $52.88 | $53.48 | $55.89 |
| Total operating expenses | $44.85 | $70.36 | $70.52 | $75.78 |
| Operating income | -$15.1 | -$42.07 | -$34.68 | -$42.89 |
| Income from continuing operations | ||||
| EBIT | -$0.16 | -$41.97 | -$48.08 | -$42.76 |
| Income tax expense | $0.24 | |||
| Interest expense | $7.46 | $12.44 | $22.46 | $13.02 |
| Net income | ||||
| Net income | -$7.87 | -$54.41 | -$70.54 | -$55.78 |
| Income (for common shares) | -$7.87 | -$54.41 | -$70.54 | -$55.78 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$2.75 | -$12.83 | -$8.11 | |
| Operating activities | ||||
| Depreciation | $0.2 | $0.21 | $0.47 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.54 | $1.58 | $0.94 | |
| Total cash flows from operations | -$7.01 | -$10.38 | -$4.94 | |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.03 | -$0.02 | |
| Investments | ||||
| Total cash flows from investing | -$0.14 | -$0.04 | -$0.03 | -$0.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.72 | $82.64 | $3.61 | |
| Net borrowings | -$0.01 | -$0.01 | $0.3 | |
| Total cash flows from financing | $83.44 | $1.71 | $81.74 | $3.91 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $54.02 | -$5.33 | $71.33 | -$1.04 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$7.87 | -$54.41 | -$70.54 | -$55.78 |
| Operating activities | ||||
| Depreciation | $1.34 | $2.39 | $2.96 | $3.44 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.69 | $4.38 | $6.82 | $6.58 |
| Total cash flows from operations | -$6.38 | -$9.79 | -$32.98 | -$45.46 |
| Investing activities | ||||
| Capital expenditures | -$0.99 | -$2.52 | -$0.91 | -$0.52 |
| Investments | ||||
| Total cash flows from investing | -$0.99 | -$2.52 | -$0.91 | -$0.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.26 | $13.59 | $30.12 | $6.21 |
| Net borrowings | -$13.27 | -$2.02 | $22.34 | |
| Total cash flows from financing | $3.97 | $11.56 | $30.11 | $28.46 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.4 | -$0.75 | -$3.78 | -$17.52 |
News
Fundamentals
| Market cap | $543.42M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 91.18M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -1.54 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.37 |
| Quick ratio | 5.91 |